Last reviewed · How we verify
NCT05124535
Population-based Age-stratified Seroepidemiological Investigation Protocol for Coronavirus 2019 (COVID-19) Infection in the Federation of Bosnia and Herzegovina
trial in Seroprevalence in 1,152 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Institute for Public Health of the Federation of Bosnia and Herzegovina |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,152 |
| Start date | 17 November 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Bosnia and Herzegovina |
Conditions studied
- Seroprevalence — all drugs for Seroprevalence →
- Antibody — all drugs for Antibody →
- COVID-19 — all drugs for COVID-19 →
Sponsor
Institute for Public Health of the Federation of Bosnia and Herzegovina
Who can join
Adults 18 to 65, any sex, with Seroprevalence or Antibody. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is the second cross-sectional study conducted in the region. In the first cross sectional study, conducted in the winter of 2020, we aimed to estimate the seroprevalence of SARS-CoV-2 IgG antibodies among blood donors in Sarajevo Canton. We also assessed immune durability among seropositive participants after 6 months. In total, of 1015 blood donors aged 18-65 years in Sarajevo Canton between 2 November and 3 December 2020 were recruited and population-weighted seroprevalence in Sarajevo Canton was 19.2% (95% CI: 16.7-21.6%). The aim of this second cross-sectional study is to measure the seroprevalence SARS-CoV-2 antibodies and assess antibody kinetics in the blood donor population after 12 months.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies.
Musa S, Catovic Baralija E, Ivey Sawin V, Nardone A, et al · · 2023 · cited 3× · PMID 37621919 · DOI 10.1111/irv.13182 -
Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: cross-sectional and longitudinal studies
Musa S, Baralija EC, Sawin VI, Nardone A, et al · · 2022 · DOI 10.22541/au.166608003.39636815/v1
Verify or expand the search:
- PubMed search for NCT05124535
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05124535 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute for Public Health of the Federation of Bosnia and Herzegovina
- Last refreshed: 18 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05124535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing